Fig. 8: ZLDI-8 enhanced the antitumor effect of Sorafenib on in vivo metastasis of LM-3 cells. | Cell Death & Disease

Fig. 8: ZLDI-8 enhanced the antitumor effect of Sorafenib on in vivo metastasis of LM-3 cells.

From: Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Fig. 8

Single cells of LM-3 was injected into nude mice’s liver via hepatic portal vein. Animals were received solvent control, ZLDI-8, Sorafenib or ZLDI-8+Sorafenib. Next, 18F-FDG/PET images (n = 5) were obtained (a) and the results of the PET were confirmed by the imagines (b) or radioactivity of ablated livers (c). d The relative nodules number was shown as quantitative results. Nodules in liver organ were confirmed by the Masson staining results (e). The inhibition rate of ZLDI-8, Sorafenib or ZLDI-8+Sorafenib was calculated from radioactivation and shown (f). The PET (b) and Masson staining (c) were also showed. The arrows indicate intrahepatic tumor nodules. *p < 0.05 vs. Sorafenib or control; *p < 0.05 vs. ZLDI-8 or control

Back to article page